Oscient Pharmaceuticals grants Factive commercialization rights to Abbott affiliate

By Lisa Kerner

Charlotte, N.C., Aug. 10 - Oscient Pharmaceuticals Corp. granted the commercialization rights to Factive (gemifloxacin mesylate) tablets in Canada to Abbott Canada, the Canadian affiliate of Abbott.

While specific financial terms were not disclosed, Abbott Canada will make certain milestone payments to Oscient, according to a company news release.

Under the agreement, Abbott Canada has access to the entire clinical trial dossier for Factive and will pursue regulatory approval for additional indications.

Factive is approved in Canada for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and in the United States for the seven-day treatment of community-acquired pneumonia of mild to moderate severity and the five-day treatment of AECB.

"Through this agreement, we are continuing to execute our strategy of building Factive into a global brand through partnerships with leading pharmaceutical companies," president and chief executive officer Steven M. Rauscher said in the release.

Oscient is a biopharmaceutical company based in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.